PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

导出 OA

翻译打印收藏纠错

第一作者： Laurie,Herviou

第一单位： IGH, CNRS, Univ Montpellier, Montpellier, France.

作者： Laurie,Herviou ^[1] ; Alboukadel,Kassambara ^[2] ; Stéphanie,Boireau ^[2] ; Nicolas,Robert ^[2] ; Guilhem,Requirand ^[2] ; Carsten,Müller-Tidow ^[3] ; Laure,Vincent ^[4] ; Anja,Seckinger ^[5] ; Hartmut,Goldschmidt ^[5] ; Guillaume,Cartron ^[6] ; Dirk,Hose ^[5] ; Giacomo,Cavalli ^[1] ; Jerome,Moreaux ^[7]

作者单位： IGH, CNRS, Univ Montpellier, Montpellier, France. ^[1] Department of Biological Hematology, CHU Montpellier, Montpellier, France.;IGH, CNRS, Univ Montpellier, Montpellier, France. ^[2] Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany. ^[3] Department of Clinical Hematology, CHU Montpellier, Montpellier, France. ^[4] Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.;Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany. ^[5] UFR de Médecine, Univ Montpellier, Montpellier, France.;Department of Clinical Hematology, CHU Montpellier, Montpellier, France.;UMR CNRS 5235, Univ Montpellier, Montpellier, France. ^[6] Department of Biological Hematology, CHU Montpellier, Montpellier, France. jerome.moreaux@igh.cnrs.fr.;IGH, CNRS, Univ Montpellier, Montpellier, France. jerome.moreaux@igh.cnrs.fr.;UFR de Médecine, Univ Montpellier, Montpellier, France. jerome.moreaux@igh.cnrs.fr.;Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Hôpital Saint-Eloi-CHRU de Montpellier, 80, av. Augustin Fliche, 34295, Montpellier, Cedex 5, France. jerome.moreaux@igh.cnrs.fr. ^[7]

关键词 Epigenetics Multiple myeloma PRC2 Predictive score